Cam acroos this from nutriotional neuroscience 2010 today:
The ScanBrit randomised, controlled, singleblind
study of a gluten- and casein-free
dietary intervention for children with autism
spectrum disorders
Paul Whiteley1, Demetrious Haracopos2, Ann-Mari Knivsberg3, Karl Ludvig
Reichelt4, Sarah Parlar2, Judith Jacobsen5, Anders Seim6, Lennart Pedersen2,
Maja Schondel2, Paul Shattock1
1Dept of Pharmacy, Health & Well-being, Faculty of Applied Sciences, University of Sunderland, UK
2Center for Autisme, Herlev Hovedgade, Herlev, Denmark
3National Centre for Reading Education & Research, University of Stavanger, Norway
4Department of Pediatric Research, University of Oslo, Rikshospitalet Medical Centre, Norway
5Statcon ApS, Kokkedal, Denmark
6Fjellstrand, Norway
There is increasing interest in the use of gluten- and casein-free diets for children with autism spectrum
disorders (ASDs).We report results froma two-stage, 24-month, randomised, controlled trial incorporating
an adaptive ?catch-up? design and interim analysis. Stage 1 of the trial saw 72 Danish children (aged 4
years to 10 years 11 months) assigned to diet (A) or non-diet (B) groups by stratified randomisation.
Autism Diagnostic Observation Schedule (ADOS) and the Gilliam Autism Rating Scale (GARS) were
used to assess core autism behaviours, Vineland Adaptive Behaviour Scales (VABS) to ascertain
developmental level, and Attention-Deficit Hyperactivity Disorder ? IV scale (ADHD-IV) to determine
inattention and hyperactivity. Participants were tested at baseline, 8, and 12 months. Based on per
protocol repeated measures analysis, data for 26 diet children and 29 controls were available at 12
months. At this point, there was a significant improvement to mean diet group scores (time*treatment
interaction) on sub-domains of ADOS, GARS and ADHD-IV measures. Surpassing of predefined
statistical thresholds as evidence of improvement in group A at 12 months sanctioned the re-assignment
of group B participants to active dietary treatment.Stage 2 data for 18 group A and 17 group B participants
were available at 24 months. Multiple scenario analysis based on inter- and intra-group comparisons
showed some evidence of sustained clinical group improvements although possibly indicative of a plateau
effect for intervention. Our results suggest that dietary intervention may positively affect developmental
outcome for some children diagnosed with ASD. In the absence of a placebo condition to the current
investigation, we are, however, unable to disqualify potential effects derived from intervention outside of
dietary changes. Further studies are required to ascertain potential best- and non-responders to
intervention.